Nexelis

Activities: Manufacturing Pharmaceutical

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Regulatory

Nexelis wins ViE award for central/specialty laboratory

The company’s VP Vaccine Sciences, Luc Gagnon, recently presented to the World Vaccine Congress alongside Valentina Bernasconi of CEPI
Ingredients

Why the production of bispecific antibodies depends on early stage product characterisation

Chloe Ackaert, Senior Scientist, and Sofie Pattijn, Chief Technology Officer and founder, ImmunXperts a Nexelis group company, explain how early development studies to evaluate functionality and immunogenicity help to derisk the manufacture of bispecific antibodies
Subscribe now